Website & contact details
- Website
Pathios Therapeutics Limited
- Incorporated
- 27 February 2017 (9 years)
- Industry
- Research and experimental development on biotechnology (72110)
- Directors
- Jon WiggintonPaul Grant HighamChristopher Dean Nave
- Accounts type
- Small
- Region
- South East
- Address
- 99 Park DriveMiltonAbingdonOX14 4RY
Filing status
- Accounts due
- 30 September 2027
- Last accounts
- 31 December 2025
- Conf. stmt due
- 12 March 2027
- Last conf. stmt
- 26 February 2026
Officers 6 active
Officer details are public data from the Companies House register.
Wigginton, Jon, Dr
Director · Appointed 14 July 2025
American
Born October 1961 (65)
Higham, Paul Grant
Director · Appointed 7 June 2024
British,German
Born December 1962 (63)
Harris, Samantha Ann
Secretary · Appointed 15 June 2022
Nave, Christopher Dean
Director · Appointed 9 September 2019
Australian
Born December 1974 (51)
American
Born March 1963 (63)
Australian
Born June 1967 (59)
Officer history (5 former)
14 July 2025
Appointed Wigginton, Jon, Dr as Director
6 March 2025
Resigned Guenot, Jeanmarie, Dr as Director
7 June 2024
7 June 2024
Appointed Higham, Paul Grant as Director
26 August 2022
Appointed Guenot, Jeanmarie, Dr as Director
15 June 2022
Appointed Harris, Samantha Ann as Secretary
15 June 2022
Resigned Mccarthy, Kirsty Ann as Secretary
22 November 2019
9 September 2019
Appointed Nave, Christopher Dean as Director
28 August 2019
28 August 2019
Resigned Unitt, John Francis, Dr as Director
28 August 2019
28 November 2018
Appointed Unitt, John Francis, Dr as Director
27 February 2017
27 February 2017
Appointed Mccarthy, Kirsty Ann as Secretary
27 February 2017
Ownership 0 active
People and entities with significant control, from the Companies House PSC register
The company has declared that it has no person with significant control.
Holdings 1
Companies where Pathios Therapeutics Limited is registered as a person with significant control
Owns 75–100% of shares
Active
Former controllers (2)
28 August 2019
Ceased Canaan XI L.P. — Owns 25–50% of shares
29 October 2018
Financials
Balance sheet as at 31 December 2025 · small accounts
- Net Assets
- £9,508,621
- Cash
- £6,250,516
- Profit
- (£7,484,693)
- Employees
- 9
- Current Ratio
- 6.0x
- Return on Equity
- -79%
Trend
Net Assets
Balance sheet detail
| 2025 | 2024 | 2023 | 2022 | 2020 | 2019 | |
|---|---|---|---|---|---|---|
| Fixed Assets | £2,500,876 | £782,132 | £42,094 | |||
| Current Assets | £8,398,831 | £4,743,394 | £4,425,537 | £4,916,916 | £3,919,408 | £2,952,080 |
| Cash | £6,250,516 | £3,250,384 | £2,784,025 | £2,533,947 | £2,098,450 | £2,439,895 |
| Creditors (< 1 year) | £1,391,086 | £677,300 | £697,281 | £807,324 | £442,515 | £101,147 |
| Net Current Assets | £7,007,745 | £4,066,094 | £3,728,256 | £4,109,592 | £3,476,893 | £2,850,933 |
| Net Assets | £9,508,621 | £4,848,226 | £3,770,350 | £4,191,216 | £3,562,947 | £2,850,933 |
| Shareholder Funds | £9,508,621 | £4,848,226 | £3,770,350 | £4,191,216 | £3,562,947 | £2,850,933 |
Filings
Filing history not loaded yet. See it on Companies House
Some other companies at this address
Other companies in this industry
Sandwich
Newcastle Upon Tyne
Edinburgh
Edinburgh
Need accounts figures, ownership or websites for thousands of companies? Bulk data & API →